Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of DCVC H1 HA mRNA-LNP Vaccine in Healthy Adults
NCT05945485Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2023
- Primary completion
- May 2026
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of DCVC H1 HA mRNA vaccine in influenza (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Adverse Events of Special Interest, Influenza Like Illnesses and 6 more. Started Oct 2023; status: completed.
02
Drugs
DCVC H1 HA mRNA vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05945485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05945485.